NCT02072018

Peyronie's Disease Treatment Protocol

A Sequential, Randomized, Double-blind, Placebo-controlled, Prospective Study to Evaluate the Safety and Efficacy of the H-100 Treatment in Adult Male Volunteers With Peyronie's Disease

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Hybrid Medical · Industry
• Sex: Male
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Treatment of Peyronie's disease remains difficult. The purpose of this study is to test the safety and efficacy of a new compound to treat this disease.

Conditions

• Peyronie's Disease

Interventions

Type	Name	Description
DRUG	H-100	H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
DRUG	Placebo	Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.

Timeline

• Start date: 2013-06-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2014-02-26
• Last updated: 2014-02-26

Locations

1 site across 1 country: United States